Scott Lopez, NP
Family · Tucson, AZNPI 1538268065
Payments from drug & device makers
What this record shows
21 manufacturers reported payments, led by AbbVie at 52.7% of the total. Reporting peaked in 2023 at $812 and has fallen 85.4% since, to $118 in 2024.
Across 59 payments — averaging $30.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$938
- Boston Scientific$144
- Abbott$110
- Johnson & Johnson$76
- Bayer$68
- Merck$62
- plus $383 from 15 others
What the payments were for
- Speaking & faculty fees$91852%
- Food & beverage$86248%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 14 | $938 |
| Boston Scientific | 7 | $144 |
| Abbott | 6 | $110 |
| Johnson & Johnson | 4 | $76 |
| Bayer | 4 | $68 |
| Merck | 4 | $62 |
| Angiodynamics, Inc. | 3 | $61 |
| Edwards Lifesciences | 2 | $47 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $45 |
| Lexicon Pharmaceuticals, Inc. | 1 | $24 |
| Impulse Dynamics (USA) Inc. | 2 | $23 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Bard Peripheral Vascular, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Novartis | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Pfizer | 1 | $16 |
| Astellas Pharma US Inc | 1 | $13 |
How this compares
$1,780 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 16 | $82 |
Paid to pharmacies, not to this prescriber.
Other family in Tucson
- Lindsay CarterTucson$108K
- Vicki McIntyreTucson$68K
- Amber KemnitzTucson$33K
- Joy BaynesTucson$30K
- Cynthia CarstenTucson$27K
- Sharon MorganTucson$22K
- Margaret SpencerTucson$19K
- Polina SamoylovaTucson$18K
- Stephanie Niemi-OlsonTucson$15K
- Cindy ChangTucson$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.